Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
about
Emerging molecularly targeted therapies in castration refractory prostate cancerPACAP inhibits tumor growth and interferes with clusterin in cervical carcinomasClusterin: a key player in cancer chemoresistance and its inhibitionDAB2IP in cancerEvolving landscape and novel treatments in metastatic castrate-resistant prostate cancerTargeting the adaptive molecular landscape of castration-resistant prostate cancerRationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancerNon-secreted clusterin isoforms are translated in rare amounts from distinct human mRNA variants and do not affect Bax-mediated apoptosis or the NF-κB signaling pathwayMouse models of colorectal cancer as preclinical modelsPlasma Clusterin and Lipid Profile: A Link with Aging and Cardiovascular Diseases in a Population with a Consistent Number of CentenariansSilencing disease genes in the laboratory and the clinicAddressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survivalNovel therapies for metastatic castrate-resistant prostate cancer.Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcomaThe role of epithelial plasticity in prostate cancer dissemination and treatment resistanceClusterin protects hepatocellular carcinoma cells from endoplasmic reticulum stress induced apoptosis through GRP78.Targeted therapy in prostate cancer.Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma.Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGFβ1 signaling to confer a pro-survival bystander effect.Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects.Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancerCytoplasmic Clusterin expression correlates with pancreatic neuroendocrine tumor size and pathological stage.Target mRNA inhibition by oligonucleotide drugs in man.Novel therapies for the treatment of advanced prostate cancer.The mechanism of DAB2IP in chemoresistance of prostate cancer cells.Potential use of custirsen to treat prostate cancer.eIF3f reduces tumor growth by directly interrupting clusterin with anti-apoptotic property in cancer cells.Overcoming HSP27-mediated resistance by altered dimerization of HSP27 using small molecules.Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.The role of chemotherapy and new targeted agents in the management of primary prostate cancer.Future directions in castrate-resistant prostate cancer therapy.Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.New developments in castrate-resistant prostate cancer.Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer.Precision medicine for prostate cancer.The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.Membrane-bound serine protease inhibitor HAI-1 is required for maintenance of intestinal epithelial integrity.
P2860
Q21284745-19630063-374B-43CB-A1AC-0AA767FE4A79Q24307847-760C99F0-63D6-4382-999B-33A9812729D0Q24567925-CAEDFAD9-BEEC-44CD-AD29-DFA1E2DD6FFDQ26776456-3D6EB4E7-A397-494F-9EB8-B8FF37C5B305Q27010542-E608918F-BE9B-46D6-BD60-17E711C32B76Q27022821-2EA49682-FDEC-4E2D-9362-68E7ADACE264Q27028084-69704AFE-EA4F-4BDD-A9B1-5E7DC32754D9Q27305342-1964218B-A265-4CE7-B5E0-BE126726B856Q28081871-8D29F046-C371-4C4B-B184-6207551F6A74Q28548345-E6C3BDFC-0300-41D6-8C76-EEDF1F769479Q29039090-437861F5-0652-4E04-B68E-001204E0FCFDQ30244818-E6FC6633-1740-4B53-AB27-05A634D7510FQ30611108-27872A30-C409-496E-9D48-499BBCED3E6EQ34249263-5C5B1E5C-5765-434F-BA2B-8140BC281DBFQ34365891-ED39B9FC-1609-4C1B-B6EB-DFCBC531F022Q34505037-BE01AD55-5520-43A8-A364-8467D5A6A1F0Q34606433-D9896940-40D8-4B32-9124-319F1BFFFE54Q34634763-AEFE560C-E27D-49FE-ADCD-F0CF209A526DQ35550129-6A017E81-BF7D-4453-89CB-EB737244D7BBQ36019718-3EDB6EED-9FAE-4394-9AE1-95A654104801Q36072471-E50EA670-B71D-4E55-9543-39AC25E3157AQ36072803-904D5C40-619C-4994-98C7-10B6882A984AQ36100952-DF833D29-1642-46A3-8C5F-5F9FD0769364Q36241242-B233251A-DEA6-47E0-A34A-134E92F773BFQ36280303-865FC98E-2AB6-4C17-9CAF-599BD0C13216Q36435109-9A91FD07-4820-4E34-A2E2-C2FF80442650Q36665708-CAF899D1-372D-416C-A831-63181EB36F71Q36725756-D9A23749-B482-451F-8D98-AB96C7B3EBE7Q36975969-B5A63D58-8F44-4D24-B751-B31AFAD6276DQ37109809-8AB82EE8-3CA5-4046-AAE5-A74170CC3F3FQ37619720-E92E3A9A-28E7-4EC5-AB67-5A63DAAC336EQ37620923-6EAE17DD-A04D-45D8-B072-3A004836446AQ37708171-4A379A08-4DD0-47A2-B703-85531D07370FQ37826274-7D3AC00A-10C4-48B2-82C3-4AB7791BA619Q37876194-1CF8A4D3-FFD1-4418-A4BC-78B6F50A1D68Q38016532-47B1DBFC-1890-4D9F-B03E-F2D8368D977BQ38069776-6638BFE9-530C-4A49-B494-7185C032CAEBQ38263711-110EC93F-35A7-4878-9E6F-EF793CD9E580Q38575004-1E3581D5-E90F-430B-A249-EA1B0E776E03Q38575459-C02D58A5-3AB0-41DA-940B-BC03556EF003
P2860
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
@en
type
label
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
@en
prefLabel
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
@en
P2093
P2860
P1476
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
@en
P2093
Amina Zoubeidi
Martin Gleave
P2860
P304
P356
10.1158/1078-0432.CCR-09-2917
P407
P577
2010-02-09T00:00:00Z